STOCK TITAN
  1. Home
  2. News
  3. CYTH

Cyclo Therapeutics, Inc. - CYTH STOCK NEWS

Welcome to our dedicated page for Cyclo Therapeutics news (Ticker: CYTH), a resource for investors and traders seeking the latest updates and insights on Cyclo Therapeutics stock.

Cyclo Therapeutics, Inc. (CYTH) is a clinical-stage biotechnology company dedicated to developing cyclodextrin-based treatments for neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company was originally organized in 1990 and began operations in 1992. Over the years, Cyclo Therapeutics has evolved into a holding company operating under various subsidiaries, including CTD, Inc.; Nanosonic Products, Inc.; Sphingo Biotech, Inc.; and Ferrazo Environmental Technologies, Inc.

The company's flagship product, Trappsol Cyclo, is at the forefront of its clinical trials for NPC treatment. Cyclo Therapeutics is committed to advancing this promising treatment through various phases of clinical testing, aiming to bring it to market to provide relief for NPC patients.

In addition to its focus on rare diseases, Cyclo Therapeutics generates revenue from the sale of cyclodextrins and related products to pharmaceutical and nutritional industries. Key products include Trappsol HPB and Trappsol Fine Chemical, which are widely used in various industries.

Recent Achievements:

  • Successfully completed Phase I clinical trials for Trappsol Cyclo.
  • Expanded partnerships with pharmaceutical companies for cyclodextrin-based product development.
  • Enhanced research and development capabilities through strategic collaborations.

Cyclo Therapeutics' commitment to innovation and its strategic approach to product development and commercialization have positioned it as a significant player in the biotechnology sector. The company remains focused on its mission to develop effective treatments for rare and neurodegenerative diseases.

News

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Rhea-AI Summary
Cyclo Therapeutics, Inc. (CYTH) and Applied Molecular Transport Inc. (AMTI) have completed a merger, forming a combined company operating as Cyclo Therapeutics with a focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1). The cash runway has been extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.1%
Tags
acquisition
-
News

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Rhea-AI Summary
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) announced positive FDA feedback from its Type C meeting, leading to a direction for the comparative interim analysis of its ongoing pivotal Phase 3 study, TransportNPC™, for the treatment of Niemann-Pick Disease Type C1 (NPC1). The FDA aligned with the company's proposal to continue with the Phase 3 96-week study, but change the timing of the planned comparative interim analysis to execute data readout in Q1 2025. The ongoing study is a randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the safety, tolerability, and efficacy of Trappsol® Cyclo™ in patients with NPC1. The Company's clinical data provided suggestive evidence of potential therapeutic benefit, and the FDA feedback allows for continued advancement of the program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
News

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Rhea-AI Summary
Cyclo Therapeutics, Inc. (CYTH) to present pivotal Phase 3 global study on Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 at the 20th Annual WORLDSymposium™
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.82%
Tags
conferences
News

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) reported strong enrollment in its pivotal Phase 3 global study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”). The company is also on track to close a merger with Applied Molecular Transport, Inc. before the year ends. Additionally, they have taken steps to strengthen their balance sheet and extend their cash position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
earnings
-
News

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Rhea-AI Summary
Cyclo Therapeutics has entered into a securities purchase agreement with accredited investors to raise $2.36 million in a private offering. The investors exercised their original warrants and received new warrants with an exercise price of $0.95 per share. The company issued new warrants to purchase a total of 3,655,694 shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.45%
Tags
management
-
News

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

Rhea-AI Summary
Cyclo Therapeutics to present at 8th Annual Dawson James Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
conferences
News

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Rhea-AI Summary
Cyclo Therapeutics and Applied Molecular Transport have entered into a merger agreement, forming Cyclo Therapeutics, Inc. The combined company will focus on advancing Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1 (NPC1). The closing of the merger is expected to result in approximately $13.7 million in cash for operations until 2H 2024. Upcoming milestones include completing enrollment in a pivotal Phase 3 clinical trial, reporting top-line data, and preparing for NDA submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
acquisition
-
News

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Cyclo Therapeutics reports strong enrollment progress in pivotal Phase 3 study for Niemann-Pick Disease Type C1
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.22%
Tags
earnings
-
News

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

Rhea-AI Summary
Cyclo Therapeutics closes private placement with Rafael Holdings for $5,000,000, to be used for working capital and Trappsol® Cyclo™ development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
none
News

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.77%
Tags
clinical trial

FAQ

What is the current stock price of Cyclo Therapeutics (CYTH)?

The current stock price of Cyclo Therapeutics (CYTH) is $0.63 as of December 20, 2024.

What is the market cap of Cyclo Therapeutics (CYTH)?

The market cap of Cyclo Therapeutics (CYTH) is approximately 18.1M.

What does Cyclo Therapeutics, Inc. specialize in?

Cyclo Therapeutics specializes in developing cyclodextrin-based treatments for neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC).

What is Trappsol Cyclo?

Trappsol Cyclo is Cyclo Therapeutics' lead drug candidate, currently undergoing clinical trials for the treatment of Niemann-Pick Type C disease (NPC).

When was Cyclo Therapeutics founded?

Cyclo Therapeutics, originally known as Cyclodextrin Technologies Development, Inc., was organized as a Florida corporation on August 9, 1990.

What are some of Cyclo Therapeutics' key products?

Key products include Trappsol HPB and Trappsol Fine Chemical, which are widely used in pharmaceutical and nutritional industries.

What are the subsidiaries of Cyclo Therapeutics?

The company operates four wholly owned subsidiaries: CTD, Inc.; Nanosonic Products, Inc.; Sphingo Biotech, Inc.; and Ferrazo Environmental Technologies, Inc.

Where does Cyclo Therapeutics generate its revenue from?

Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries.

What recent achievements has Cyclo Therapeutics accomplished?

Recent achievements include completing Phase I clinical trials for Trappsol Cyclo, expanding partnerships, and enhancing R&D capabilities.

What is the focus of Cyclo Therapeutics' research?

The company's research focuses on developing and commercializing cyclodextrin-based treatments for rare and neurodegenerative diseases.

How does Cyclo Therapeutics contribute to healthcare?

Cyclo Therapeutics aims to bring effective treatments to market, particularly for rare diseases like Niemann-Pick Type C disease, thereby improving patient outcomes.

What is the significance of cyclodextrins in Cyclo Therapeutics' products?

Cyclodextrins are key components in the company's treatments and products, used for their ability to enhance drug delivery and efficacy.

Stock CYTH logo
Cyclo Therapeutics, Inc.

Nasdaq:CYTH

CYTH Rankings

#5349 Ranked by Market Cap
N/A Ranked by Dividends

CYTH Stock Data

18.08M
17.10M
40.08%
13.17%
0.4%
Drug Manufacturers - Specialty & Generic
Biological Products, (no Disgnostic Substances)
Link
United States of America
GAINESVILLE